pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
Jakavi 15 mg tablets, Placebo of Jakavi 15mg
Phase 2 · small molecule · Inclusion body Myositis
Jakavi 15 mg tablets, Placebo of Jakavi 15mg for Inclusion body Myositis is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP220829
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Inclusion body Myositis
- Status
- active
- Trials
- 1